Viable manufacture of cell therapies through the integration of multiple unit processes onto a counter-flow centrifugation device
January 27-31, 2019
With growing proof of efficacy in varied indications, regenerative medicine has reached a positive inflection point in the investment of time and money by established industry leaders and disruptive startups. With rapid growth comes the need to devote resources to the engineering challenges that currently prevent the quick and cost-effective manufacture of therapies that maintain a consistent, high-level of quality and, in turn, can support commercial manufacturing. This is especially true when looking at patient specific cell therapies that require rapid change over of equipment and benefit little from traditional sterile barriers (i.e. filters and heat inactivation). Counter-flow centrifugation (CFC) presents an intriguing technology that, when implemented using closed and automated system, provides a platform for upstream and downstream processing of cellular therapies by incorporating multiple unit processes and mitigating the risk imposed with manual equipment transfers.
Please click Additional Files below to see the full abstract.
Alexander S. Klarer and David Smith, "Viable manufacture of cell therapies through the integration of multiple unit processes onto a counter-flow centrifugation device" in "Advancing Manufacture of Cell and Gene Therapies VI", Dolores Baksh, GE Healthcare, USA Rod Rietze, Novartis, USA Ivan Wall, Aston University, United Kingdom Eds, ECI Symposium Series, (2019). https://dc.engconfintl.org/cell_gene_therapies_vi/57